Original Article
Clinical efficacy and safety of a new epalrestat in diabetic peripheral neuropathy—a multicenter and ran-domized controlled clinical trial
Zhimin Liu, Ping Feng, Zhizhou Shen, Shengli Yan, Junjiang Liu
Published 2018-02-25
Cite as Chin J Endocr Surg, 2018, 12(1): 61-64,69. DOI: 10.3760/cma.j.issn.1674-6090.2018.01.015
Abstract
ObjectiveTo evaluate the efficacy and safety of new epalrestat on diabetic peripheral neuropathy (DPN) compared with Tang Lin.
MethodsA total of 235 patients with DPN were enrolled in our study. They were randomly divided into two groups: the new epalrestat group (n=117) and the Tang Lin group (n=118) . Their clinical, biochemistry, electrocardiogram, clinical symptoms and physical examinations, by using Michigan Neuropathy Screening Instrument (MNSI) , and electrophysiological assessments were performed.
ResultsThe mean changes of MNSI scores both decreased compared with baseline in two groups after treatment for 12 weeks (P<0.05) and nerve conduction velocity improved in the two groups (P<0.05) , but there were no difference of MNSI scores and nerve conduction velocity between the two groups. There was no difference of adverse event, blood pressure, heart rate, blood and urine routine examinations, liver and renal function between the two groups.
ConclusionThe new epalrestat is effective and safe as Tang Lin in treatment of DPN.
Key words:
Epalrestat; Diabetic peripheral neuropathy; Efficacy
Contributor Information
Zhimin Liu
Department of Endocrinology, Shanghai Changzheng Hospital, Shanghai 200003, China
Ping Feng
Department of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300192, China
Zhizhou Shen
Department of Endo-crinology, Shanghai Huashan hospital, Shanghai 200041, China
Shengli Yan
Department of Endocrinology, the Affili-ated Hospital of Medical College Qingdao University, Shandong 266071, China
Junjiang Liu
Department of Endocrinol-ogy, Hebei General Hospital, Hebei 050057, China